HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations.

Abstract
Epigenetic status-altering mutations in chromatin-modifying enzymes are a feature of human diseases, including many cancers. However, the functional outcomes and cellular dependencies arising from these mutations remain unresolved. In this study, we investigated cellular dependencies, or vulnerabilities, that arise when enhancer function is compromised by loss of the frequently mutated COMPASS family members MLL3 and MLL4. CRISPR dropout screens in MLL3/4-depleted mouse embryonic stem cells (mESCs) revealed synthetic lethality upon suppression of purine and pyrimidine nucleotide synthesis pathways. Consistently, we observed a shift in metabolic activity toward increased purine synthesis in MLL3/4-KO mESCs. These cells also exhibited enhanced sensitivity to the purine synthesis inhibitor lometrexol, which induced a unique gene expression signature. RNA-Seq identified the top MLL3/4 target genes coinciding with suppression of purine metabolism, and tandem mass tag proteomic profiling further confirmed upregulation of purine synthesis in MLL3/4-KO cells. Mechanistically, we demonstrated that compensation by MLL1/COMPASS was underlying these effects. Finally, we demonstrated that tumors with MLL3 and/or MLL4 mutations were highly sensitive to lometrexol in vitro and in vivo, both in culture and in animal models of cancer. Our results depicted a targetable metabolic dependency arising from epigenetic factor deficiency, providing molecular insight to inform therapy for cancers with epigenetic alterations secondary to MLL3/4 COMPASS dysfunction.
AuthorsZibo Zhao, Kaixiang Cao, Jun Watanabe, Cassandra N Philips, Jacob M Zeidner, Yukitomo Ishi, Qixuan Wang, Sarah R Gold, Katherine Junkins, Elizabeth T Bartom, Feng Yue, Navdeep S Chandel, Rintaro Hashizume, Issam Ben-Sahra, Ali Shilatifard
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 133 Issue 13 (07 03 2023) ISSN: 1558-8238 [Electronic] United States
PMID37252797 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Histone-Lysine N-Methyltransferase
  • MLL4 protein, mouse
Topics
  • Humans
  • Animals
  • Mice
  • Proteomics
  • Histone-Lysine N-Methyltransferase (genetics)
  • Mutation
  • Neoplasms (genetics)
  • Epigenesis, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: